AngioDynamics (ANGO) is a leading medical technology company focused on developing, manufacturing, and selling a wide range of medical, surgical, and diagnostic devices. These devices are primarily used by healthcare providers for vascular access, the treatment of peripheral vascular disease, and in oncology and surgical settings. The company's products are generally used in minimally invasive, image-guided procedures, and many are intended for single use or temporary implantation for short- or long-term use.
- Med Device - Offers mature products for vascular access, peripheral vascular disease, and oncology devices, providing stable solutions for healthcare providers.
- Med Tech - Focuses on high-growth, clinically differentiated platform technologies such as Auryon, NanoKnife, and Mechanical Thrombectomy systems, aimed at innovative solutions for cardiovascular disease and cancer treatment.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
James C. Clemmer ExecutiveBoard | President and Chief Executive Officer (CEO) | CEO of AngioDynamics since April 2016. Previously held executive roles at Covidien plc and Kendall Healthcare. | View Report → | |
Chad T. Campbell Executive | Senior Vice President and General Manager, Oncology and Interventional Devices | Chad T. Campbell joined AngioDynamics in May 2016 and currently serves as Senior Vice President and General Manager, Oncology and Interventional Devices; he expanded his responsibilities in October 2021 to include the Oncology Global Business Unit. | ||
Laura Piccinini Executive | Senior Vice President and General Manager for Cardiovascular and International | Laura Piccinini serves as the Senior Vice President and General Manager for Cardiovascular and International at AngioDynamics since January 2024. Previously, she served as Senior Vice President and General Manager for International since June 2021, and she brings over 25 years of leadership in the medical device industry. | ||
Lawrence T. Weiss Executive | Senior Vice President, Chief Legal Officer, and Corporate Secretary | Lawrence T. Weiss has been serving as Senior Vice President, Chief Legal Officer, and Corporate Secretary at AngioDynamics since December 2024. He previously held key legal roles at Butterfly Network, Inc., Emulate, Inc., and Analog Devices, Inc.. | ||
Stephen A. Trowbridge Executive | Executive Vice President and Chief Financial Officer (CFO) | Stephen A. Trowbridge is the Executive Vice President and Chief Financial Officer (CFO) at AngioDynamics since February 2020, managing the legal function and having served as Interim CFO since October 2019. He joined AngioDynamics in June 2008 as Corporate Counsel and later served as Senior Vice President and General Counsel. | ||
Warren G. Nighan Executive | Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs | Warren G. Nighan has served as Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs at AngioDynamics since March 2024, and previously as Senior Vice President of Quality and Regulatory Affairs starting in April 2017. |
- Given the ongoing regulatory discussions for the ancillary blood return version of AlphaVac, can you explain the hurdles you anticipate and the specific clinical data requirements that might be needed to secure a five-ten product approval?
- With tariffs already impacting gross margins and projections for FY 2026 ranging between $4,000,000 to $6,000,000 in additional costs, how do you plan to mitigate these impacts while maintaining profitability targets?
- As your manufacturing transfer process has begun to yield cost benefits, can you detail the incremental savings expected in the second half of FY 2026 and how these will bolster your overall margin outlook?
- Although AURYON is growing steadily domestically, what specific strategies are you using to accelerate international adoption and increase its contribution outside the U.S., especially in light of competitive pressures in Europe?
- While you emphasized a focus on executing with your existing medtech portfolio, are there any plans to pursue strategic acquisitions or divestitures that could further optimize growth and efficiency across your med device and medtech segments?
Research analysts covering AngioDynamics Inc.
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This competitor is one of the primary companies AngioDynamics faces in the medical device industry, which is characterized by rapid technological change and intense competition. | |
Cook Medical | This competitor operates in the same markets as AngioDynamics, which are marked by evolving customer needs and expectations. |
Medical Components, Inc. (MedComp) | This competitor is noted as one of the primary rivals in the medical device industry, competing on factors such as quality, clinical outcomes, and cost-effectiveness. |
This competitor is part of the competitive landscape AngioDynamics navigates, which includes both large and small manufacturers. | |
This competitor is highlighted as one of the significant players in the medical device industry, which requires companies to compete on innovation and price. | |
This competitor is among the large manufacturers with multiple business lines that AngioDynamics competes against in the medical device market. | |
This competitor is part of the competitive environment and is noted for its presence in the same markets as AngioDynamics. | |
Terumo Medical Corporation | This competitor is one of the companies AngioDynamics faces in the competitive medical device industry. |
This competitor is a large manufacturer with multiple business lines, competing with AngioDynamics in the medical device sector. | |
This competitor is part of the competitive landscape in the medical device industry, which is characterized by rapid technological advancements. | |
This competitor is noted as one of the significant players in the medical device market, competing on factors such as quality and innovation. | |
This competitor is part of the competitive environment AngioDynamics operates in, which includes a mix of large and small manufacturers. | |
Varian Medical Systems | This competitor is highlighted as one of the companies AngioDynamics competes against in the medical device industry. |
This competitor is a significant player in the medical device market, competing with AngioDynamics on innovation and cost-effectiveness. | |
Total Vein Systems | This competitor is part of the competitive landscape in the medical device industry, which requires companies to adapt to changing customer needs. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
QX Medical asset acquisition | 2022 | The acquisition involved a $5.0 million draw on the Revolving Facility and $3.6 million of cash usage in the first quarter of fiscal year 2022, though no additional strategic rationale or asset details were provided. |
Camaro support catheter (Syntrax) acquisition from QX Medical, LLC | 2021 | Completed on July 27, 2021, the deal had an aggregate price of $4.0 million (with $3.6 million upfront, $0.4 million holdbacks, and $1.0 million contingent consideration) to support the Auryon product family via an asset purchase, including key intangible assets amortized over 15 years and funded by a $5.0 million draw on the Revolving Facility. |
Recent press releases and 8-K filings for ANGO.
- AngioDynamics is undergoing a strategic transformation, shifting its focus to higher-margin, higher-growth areas within its Med Tech segment, which has achieved a 25% CAGR over the last five years.
- For fiscal year 2026, the company projects total revenue between $305 million and $310 million, with its high-growth Med Tech business expected to increase 12% to 15% year-over-year, while the Med Device segment is anticipated to remain roughly flat.
- The company expects to be cash flow positive for the full fiscal year 2026, despite an anticipated cash utilization of approximately $20 million in Q1 FY26, and does not plan to use its revolver.
- Key Med Tech products are expected to drive future growth, including AlphaVac and AngioVac, which are projected to generate over $50 million in revenue in FY26, and NanoKnife, which anticipates double-digit growth in probes following the implementation of a new CPT code on January 1, 2026.
- AngioDynamics, Inc. entered into a new Credit Agreement on May 28, 2025, with JPMorgan Chase Bank, N.A., providing a $25 million secured revolving credit facility.
- The Revolving Facility has a maturity date of May 28, 2027.
- During an initial "Availability Block Period," the facility will be reduced by $5,000,000 until the company demonstrates a fixed charge coverage ratio greater than 1:10 to 1.00.
- The proceeds from the Revolving Facility are intended for working capital and general corporate needs of AngioDynamics and its subsidiaries.
- The Credit Agreement includes a financial covenant requiring AngioDynamics to maintain a fixed charge coverage ratio of not less than 1.05 to 1.00 after the Availability Block Period.